Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations and Investigations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, there was a risk of a civil lawsuit being filed, which led to a significant drop in the company's stock price [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific announced it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a lawsuit still exists [4]. - The announcement of the settlement led to a further decline in Semler Scientific's stock price, falling by $3.40 per share, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Class Action Participation - Shareholders of Semler Scientific may be eligible to participate in the class action lawsuit, with a deadline to submit paperwork by October 28, 2025, to serve as lead plaintiff [5].

Group 1 - A class action lawsuit has been filed against Semler Scientific, Inc. for securities purchased between March 10, 2021, and April 15, 2025, inclusive [1] - Investors who purchased Semler Scientific securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - Investors interested in joining the class action can do so by visiting the provided link or contacting the firm directly [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Group 1 - A securities class action lawsuit has been filed against Semler Scientific, Inc. for the period between March 10, 2021, and April 15, 2025 [1] - The complaint alleges that Semler Scientific failed to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [2] - Defendants' public statements are claimed to be materially false and misleading due to the lack of disclosure about the investigation [2] Group 2 - Investors who acquired shares of Semler Scientific are encouraged to contact the law firm before the lead plaintiff motion deadline of October 28, 2025 [3] - The lead plaintiff will act on behalf of other class members in directing the litigation [3]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged violations of federal securities laws during the defined class period [1][2][3] Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Semler Scientific securities between March 10, 2021, and April 15, 2025 [2] - Allegations include that Semler Scientific failed to disclose a material investigation by the DOJ regarding violations of the False Claims Act, leading to materially false and misleading public statements [3] Group 2: Next Steps for Investors - Investors who suffered losses in Semler Scientific have until October 28, 2025, to request appointment as lead plaintiff in the case [4] - A copy of the Complaint can be reviewed on the law firm's website [4] Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5] - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6]

Core Points - A shareholder class action lawsuit has been filed against Semler Scientific, alleging that the company made materially false and misleading statements regarding a DOJ investigation into violations of the False Claims Act [1] - The lawsuit claims that Semler Scientific failed to disclose the material investigation while discussing potential violations in hypothetical terms, leading to misleading public statements [1] Legal Context - Shareholders who purchased shares of Semler Scientific between March 10, 2021, and April 15, 2025, and suffered significant losses are encouraged to seek legal advice [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is October 28, 2025 [3] Law Firm Information - Holzer & Holzer, LLC is representing the shareholders in this litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Semler Scientific, Inc. securities between March 10, 2021, and April 15, 2025, due to alleged misleading statements and undisclosed investigations by the DOJ [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Semler Scientific failed to disclose a material investigation by the DOJ regarding violations of the False Claims Act, leading to materially false and misleading public statements [5]. - Investors who purchased Semler Scientific securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by October 28, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, the company faced a risk of a civil lawsuit, leading to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the settlement announcement, Semler Scientific's stock price fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4].

Core Viewpoint - Semler Scientific, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose a significant investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Semler Scientific securities between March 10, 2021, and April 15, 2025 [1]. - Investors have until October 28, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations and Investigations - The lawsuit claims that during the class period, the company made false statements and did not disclose a civil investigative demand from the DOJ regarding improper marketing of devices as reimbursable by Medicare [3][4]. - On February 28, 2025, Semler disclosed the DOJ's investigation, which led to a stock price drop of over 9% [4]. Group 3: Settlement and Financial Impact - On April 15, 2025, Semler announced a settlement agreement of $29.75 million to resolve all claims, resulting in a nearly 10% decline in the company's stock price [5].

Core Insights - Semler Scientific reported a GAAP EPS of $5.04 for Q2 2025, significantly exceeding analyst expectations of a loss of $0.22 per share, primarily driven by $83.8 million in unrealized gains from bitcoin holdings [1][5] - The company's healthcare revenue fell to $8.2 million, below the consensus estimate of $8.4 million, marking a 43.3% decline year-over-year [2][6] - The shift towards bitcoin as a primary treasury asset has reshaped Semler's financial profile, with operational improvements in healthcare necessary to stabilize performance [4][13] Financial Performance - Q2 2025 GAAP EPS was $5.04, compared to $0.00 in Q2 2024 [2] - Revenue for Q2 2025 was $8.2 million, down from $14.5 million in Q2 2024 [2] - Net income for Q2 2025 was $66.9 million, a significant increase from $0.01 million in Q2 2024 [2] - Total operating expenses rose 13.2% year-over-year to $10.3 million, with G&A costs more than doubling to $5.1 million [2][6] Business Strategy - Semler has pivoted to bitcoin investing, acquiring 1,444 bitcoins for $149.6 million during the quarter, with total holdings growing to 5,021 bitcoins valued at $586.2 million as of July 31, 2025 [9][10] - The healthcare segment continues to face challenges, with a 43% decline in revenue attributed to reimbursement changes from CMS and high customer concentration risk [6][11] - The company launched CardioVanta to address heart failure and cardiac arrhythmia but has yet to see significant revenue impact from this initiative [7][12] Regulatory and Legal Challenges - Semler is facing ongoing legal costs, including a $29.75 million contingent liability related to a DOJ investigation, which continues to affect financial performance [8][10] - The company is preparing for potential regulatory changes that could impact both its healthcare and cryptocurrency operations [8][16] Future Outlook - Management did not provide specific guidance for future revenue or income, emphasizing continued bitcoin purchases and regulatory efforts for new QuantaFlo indications [15][16] - The company's future performance is highly dependent on external factors, including bitcoin price fluctuations and regulatory developments in healthcare and cryptocurrency [16]

Financial Data and Key Metrics Changes - For Q2 2025, the company reported total revenues of $8.2 million, a decrease compared to 2024 due to the phase-in of the 2024 CMS rate announcement impacting reimbursement for positive PAD patients [27] - The net income for Q2 2025 was $66.9 million, translating to $5.71 per basic share and $5.4 per fully diluted share [29] - The company recorded a net unrealized gain of $83.8 million from the change in fair value of Bitcoin holdings during the second quarter [29] Business Line Data and Key Metrics Changes - The healthcare business generated record cash flow of $24 million in 2024, but faced headwinds in 2025 [11][12] - The company acquired 1,444 Bitcoin in Q2 at a total cost of $149.6 million, with a total of 4,636 Bitcoin valued at $496.9 million as of June 30, 2025 [30] Market Data and Key Metrics Changes - The company held 5,021 Bitcoin valued at approximately $586.2 million as of July 31, 2025, with a cost basis of $476 million, resulting in an unrealized gain of $110 million [13][30] - The Bitcoin yield for the year to date through July 31, 2025, was 31.3%, translating into a Bitcoin dollar gain of $84 million [31] Company Strategy and Development Direction - The company aims to accumulate 10,000 Bitcoin by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027 [14] - A wholly owned subsidiary, CardioVanta, was formed to focus on early detection of heart failure and cardiac arrhythmia, with plans to seek outside capital [32] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the healthcare business to generate meaningful cash flow, which will enable further Bitcoin acquisitions [6] - The company believes that the current stock valuation is disconnected from its underlying performance and intrinsic value, indicating a commitment to unlocking value for shareholders [10] Other Important Information - The company has strengthened its Bitcoin team by adding notable figures in the Bitcoin space, enhancing its strategic direction [7] - The company is actively exploring a wide range of financing options to amplify shareholder returns [11] Q&A Session Summary Question: Are there concerns about a potential supply glut of public companies pursuing similar Bitcoin treasury strategies? - Management is not concerned, viewing other companies as peers that accelerate Bitcoin adoption [34] Question: Will there be more regular Bitcoin acquisition announcements? - The company does not plan to make weekly announcements but expects an increase in both regularity and size of announcements over time [36] Question: How does management view the MNAV multiple at which the company trades relative to its peers? - Management explained the two strategies of Bitcoin treasury companies, emphasizing the potential for intelligent leverage to amplify future returns [38][40]